Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Aurora Cannabis call volume above normal and directionally bullish » 11:45
08/14/20
08/14
11:45
08/14/20
11:45
ACB

Aurora Cannabis

$10.62 /

+0.425 (+4.17%)

Bullish option flow…

Bullish option flow detected in Aurora Cannabis with 6,207 calls trading, 1.3x expected, and implied vol increasing over 13 points to 163.80%. Aug-20 11 calls and 8/14 weekly 10.5 calls are the most active options, with total volume in those strikes near 1,900 contracts. The Put/Call Ratio is 0.11. Earnings are expected on September 10th.

ShowHide Related Items >><<
ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

07/15/20 Alliance Global Partners
Aphria better served staying 'nimble' right now, says Alliance Global Partners
07/15/20 Scotiabank
Aurora Cannabis, Aphria merger would make sense, says Scotiabank
07/15/20 Stifel
Aurora, Aphria merger could still come to fruition, says Stifel
06/24/20
Fly Intel: Top five analyst upgrades
ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

ACB Aurora Cannabis
$10.62 /

+0.425 (+4.17%)

Yesterday
Downgrade
Alliance Global downgrades Evolution Petroleum to Neutral on Delhi uncertainty » 13:23
08/13/20
08/13
13:23
08/13/20
13:23
EPM

Evolution Petroleum

$2.83 /

+0.05 (+1.80%)

, DNR

Denbury Resources

$0.00 /

+ (+0.00%)

As previously reported,…

As previously reported, Alliance Global Partners analyst Bhakti Pavani downgraded Evolution Petroleum (EPM) to Neutral from Buy after the operator of the Delhi Field, Denbury Resources (DNR), recently entered into a restructuring support agreement that "significantly increased" the uncertainty and risk for Evolution given that Delhi is its primary asset and accounts for a majority of its revenue. Although Evolution "has a pristine balance sheet and is in strong financial health," Pavani sees a Neutral rating as more appropriate given the uncertainty surrounding the operations at Delhi.

ShowHide Related Items >><<
DNR Denbury Resources
$0.00 /

+ (+0.00%)

EPM Evolution Petroleum
$2.83 /

+0.05 (+1.80%)

08/13/20 Alliance Global Partners
Evolution Petroleum downgraded to Neutral from Buy at Alliance Global Partners
05/08/20 Alliance Global Partners
Evolution Petroleum price target lowered to $4.50 from $7.50 at Alliance Global
03/13/20 Roth Capital
Evolution Petroleum downgraded to Neutral from Buy at Roth Capital
DNR Denbury Resources
$0.00 /

+ (+0.00%)

03/31/20 Stifel
Denbury Resources downgraded to Sell from Hold at Stifel
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Denbury Resources downgraded to Underweight from Equal Weight at Stephens
DNR Denbury Resources
$0.00 /

+ (+0.00%)

DNR Denbury Resources
$0.00 /

+ (+0.00%)

DNR Denbury Resources
$0.00 /

+ (+0.00%)

Downgrade
Evolution Petroleum downgraded to Neutral from Buy at Alliance Global Partners » 13:18
08/13/20
08/13
13:18
08/13/20
13:18
EPM

Evolution Petroleum

$2.83 /

+0.05 (+1.80%)

Alliance Global Partners…

Alliance Global Partners analyst Bhakti Pavani downgraded Evolution Petroleum to Neutral from Buy.

ShowHide Related Items >><<
EPM Evolution Petroleum
$2.83 /

+0.05 (+1.80%)

05/08/20 Alliance Global Partners
Evolution Petroleum price target lowered to $4.50 from $7.50 at Alliance Global
03/13/20 Roth Capital
Evolution Petroleum downgraded to Neutral from Buy at Roth Capital
On The Fly
Rising High: An exclusive talk with Cresco Labs co-founder Joe Caltabiano » 11:38
08/13/20
08/13
11:38
08/13/20
11:38
CRLBF

Cresco Labs

$0.00 /

+ (+0.00%)

, APHA

Aphria

$4.64 /

+0.13 (+2.89%)

, ACB

Aurora Cannabis

$10.04 /

+0.23 (+2.34%)

, CVSI

CV Sciences

$0.00 /

+ (+0.00%)

, CTST

CannTrust

$0.64 /

+ (+0.00%)

, CGC

Canopy Growth

$17.33 /

+0.08 (+0.46%)

, CRON

Cronos Group

$5.81 /

+0.02 (+0.35%)

, CANN

General Cannabis

$0.00 /

+ (+0.00%)

, IGC

India Globalization Capital

$3.11 /

+0.53 (+20.54%)

, TLRY

Tilray

$7.13 /

+0.23 (+3.33%)

, TCNNF

Trulieve Cannabis

$0.00 /

+ (+0.00%)

, ZYNE

Zynerba

$3.88 /

-0.07 (-1.77%)

In this edition of…

Open Full Text

ShowHide Related Items >><<
ZYNE Zynerba
$3.88 /

-0.07 (-1.77%)

TLRY Tilray
$7.13 /

+0.23 (+3.33%)

TCNNF Trulieve Cannabis
$0.00 /

+ (+0.00%)

IGC India Globalization Capital
$3.11 /

+0.53 (+20.54%)

CVSI CV Sciences
$0.00 /

+ (+0.00%)

CTST CannTrust
$0.64 /

+ (+0.00%)

CRON Cronos Group
$5.81 /

+0.02 (+0.35%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

CANN General Cannabis
$0.00 /

+ (+0.00%)

APHA Aphria
$4.64 /

+0.13 (+2.89%)

ACB Aurora Cannabis
$10.04 /

+0.23 (+2.34%)

CRLBF Cresco Labs
$0.00 /

+ (+0.00%)

07/22/20 Stifel
Cresco Labs re-initiated with a Buy at Stifel
07/07/20 Stifel
Stifel suspends coverage of cannabis names after analyst death
06/12/20 Needham
Cresco Labs initiated with a Hold at Needham
04/28/20 Canaccord
Cresco Labs price target lowered to C$11.50 from C$12.50 at Canaccord
APHA Aphria
$4.64 /

+0.13 (+2.89%)

07/30/20 CIBC
Aphria price target raised to C$7.50 from C$6 at CIBC
07/16/20 Cantor Fitzgerald
Aphria price target raised to C$10.50 from C$9.55 at Cantor Fitzgerald
07/15/20 Alliance Global Partners
Aphria better served staying 'nimble' right now, says Alliance Global Partners
07/15/20 Scotiabank
Aurora Cannabis, Aphria merger would make sense, says Scotiabank
ACB Aurora Cannabis
$10.04 /

+0.23 (+2.34%)

07/15/20 Stifel
Aurora, Aphria merger could still come to fruition, says Stifel
06/24/20
Fly Intel: Top five analyst upgrades
CVSI CV Sciences
$0.00 /

+ (+0.00%)

06/12/20 Cowen
CV Sciences initiated with a Market Perform at Cowen
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
04/07/20 Cantor Fitzgerald
CV Sciences a takeover target after patent approval, says Cantor Fitzgerald
03/17/20 Roth Capital
CV Sciences downgraded to Neutral from Buy at Roth Capital
CTST CannTrust
$0.64 /

+ (+0.00%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

08/11/20 Canaccord
Canopy Growth price target raised to C$22 from C$21 at Canaccord
07/02/20 HSBC
Constellation Brands price target raised to $170 from $147 at HSBC
06/24/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$29 from C$27 at Cantor Fitzgerald
06/01/20 Canaccord
Canopy Growth price target lowered to C$21 from C$23 at Canaccord
CRON Cronos Group
$5.81 /

+0.02 (+0.35%)

06/24/20 Raymond James
Cronos Group upgraded to Outperform from Market Perform at Raymond James
04/27/20 Raymond James
Cronos Group downgraded to Market Perform from Outperform at Raymond James
04/14/20 Piper Sandler
Piper Sandler downgrades Cronos to Neutral on delayed CBD launch
CANN General Cannabis
$0.00 /

+ (+0.00%)

11/05/19 BofA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
10/10/19 Stifel
Hexo miss further damages cannabis industry credibility, says Stifel
09/26/19 Compass Point
Cannabis banking bill should find path to passage in Senate, says Compass Point
IGC India Globalization Capital
$3.11 /

+0.53 (+20.54%)

TLRY Tilray
$7.13 /

+0.23 (+3.33%)

05/27/20 Roth Capital
Roth Capital sees Tilray operational moves as 'positive'
05/19/20 MKM Partners
Tilray price target raised to $8 from $5 at MKM Partners
05/12/20 Alliance Global Partners
Tilray price target lowered to $9 from $15 at Alliance Global Partners
05/12/20 Stifel
Tilray price target raised to $6.50 from $5.50 at Stifel
TCNNF Trulieve Cannabis
$0.00 /

+ (+0.00%)

08/12/20 Craig-Hallum
Trulieve Cannabis price target raised to $40 from $20 at Craig-Hallum
07/22/20 Stifel
Trulieve Cannabis re-initiated with a Buy at Stifel
06/22/20 AltaCorp
Trulieve Cannabis initiated with an Outperform at AltaCorp
ZYNE Zynerba
$3.88 /

-0.07 (-1.77%)

07/01/20 H.C. Wainwright
Zynerba market cap 'greatly underprices' potential, says H.C. Wainwright
07/01/20 Canaccord
Zynerba price target lowered to $12 from $18 at Canaccord
07/01/20 Needham
Zynerba downgraded to Hold from Buy at Needham
07/01/20 Needham
Zynerba downgraded to Hold from Buy at Needham
ZYNE Zynerba
$3.88 /

-0.07 (-1.77%)

TLRY Tilray
$7.13 /

+0.23 (+3.33%)

CVSI CV Sciences
$0.00 /

+ (+0.00%)

CRON Cronos Group
$5.81 /

+0.02 (+0.35%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

APHA Aphria
$4.64 /

+0.13 (+2.89%)

ACB Aurora Cannabis
$10.04 /

+0.23 (+2.34%)

CVSI CV Sciences
$0.00 /

+ (+0.00%)

CTST CannTrust
$0.64 /

+ (+0.00%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

APHA Aphria
$4.64 /

+0.13 (+2.89%)

TLRY Tilray
$7.13 /

+0.23 (+3.33%)

CRLBF Cresco Labs
$0.00 /

+ (+0.00%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

APHA Aphria
$4.64 /

+0.13 (+2.89%)

ZYNE Zynerba
$3.88 /

-0.07 (-1.77%)

TLRY Tilray
$7.13 /

+0.23 (+3.33%)

CTST CannTrust
$0.64 /

+ (+0.00%)

CRON Cronos Group
$5.81 /

+0.02 (+0.35%)

CGC Canopy Growth
$17.33 /

+0.08 (+0.46%)

APHA Aphria
$4.64 /

+0.13 (+2.89%)

ACB Aurora Cannabis
$10.04 /

+0.23 (+2.34%)

Recommendations
Yelp price target raised to $28 from $26 at DA Davidson » 09:22
08/13/20
08/13
09:22
08/13/20
09:22
YELP

Yelp

$23.44 /

+0.1 (+0.43%)

DA Davidson analyst Tom…

DA Davidson analyst Tom Forte raised the firm's price target on Yelp to $28 from $26 and keeps a Buy rating on the shares. The analyst notes his updated discounted cash flow analysis model and also cites a cost-structure-driven margin expansion, continued growth of strategic partnerships, and greater attention on advertisers and business owners as some of the company's potential catalysts.

ShowHide Related Items >><<
YELP Yelp
$23.44 /

+0.1 (+0.43%)

YELP Yelp
$23.44 /

+0.1 (+0.43%)

08/07/20 RBC Capital
Yelp price target raised to $29 from $21 at RBC Capital
08/06/20 Baird
Yelp price target raised to $26 from $22 at Baird
06/10/20 BTIG
Yelp initiated with a Neutral at BTIG
06/10/20 Citi
Yelp price target raised to $26 from $21 at Citi
YELP Yelp
$23.44 /

+0.1 (+0.43%)

YELP Yelp
$23.44 /

+0.1 (+0.43%)

YELP Yelp
$23.44 /

+0.1 (+0.43%)

YELP Yelp
$23.44 /

+0.1 (+0.43%)

Recommendations
Groupon price target raised to $36 from $32 at DA Davidson » 09:15
08/13/20
08/13
09:15
08/13/20
09:15
GRPN

Groupon

$23.74 /

-1.66 (-6.54%)

DA Davidson analyst Tom…

DA Davidson analyst Tom Forte raised the firm's price target on Groupon to $36 from $32 and keeps a Buy rating on the shares. The analyst notes his updated discounted cash flow analysis model and also cites an improved customer experience, better international results, as well as the reduced conversion gap between mobile and desktop platforms as some of the company's potential catalysts.

ShowHide Related Items >><<
GRPN Groupon
$23.74 /

-1.66 (-6.54%)

GRPN Groupon
$23.74 /

-1.66 (-6.54%)

08/11/20 Wedbush
Groupon price target raised to $27 from $22 at Wedbush
06/18/20 Wedbush
Groupon price target lowered to $22 from $35 at Wedbush
06/18/20 Barclays
Groupon business model remains uncertain, says Barclays
06/17/20 DA Davidson
Groupon price target raised to $32 from $23 at DA Davidson
GRPN Groupon
$23.74 /

-1.66 (-6.54%)

GRPN Groupon
$23.74 /

-1.66 (-6.54%)

GRPN Groupon
$23.74 /

-1.66 (-6.54%)

GRPN Groupon
$23.74 /

-1.66 (-6.54%)

Recommendations
Fate Therapeutics price target raised to $40 from $32 at Cantor Fitzgerald » 07:21
08/13/20
08/13
07:21
08/13/20
07:21
FATE

Fate Therapeutics

$34.17 /

-0.51 (-1.47%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Fate Therapeutics to $40 from $32 and keeps an Overweight rating on the shares. The analyst says Fate continues to make progress dosing patients across many of its programs and remains focused on updates for FT596, FT819, and FT538, where she thinks that the products could be escalated up to efficacious doses relatively quickly.

ShowHide Related Items >><<
FATE Fate Therapeutics
$34.17 /

-0.51 (-1.47%)

FATE Fate Therapeutics
$34.17 /

-0.51 (-1.47%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
FATE Fate Therapeutics
$34.17 /

-0.51 (-1.47%)

  • 09
    Jun
  • 12
    Sep
FATE Fate Therapeutics
$34.17 /

-0.51 (-1.47%)

Wednesday
Hot Stocks
Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant » 13:55
08/12/20
08/12
13:55
08/12/20
13:55
FATE

Fate Therapeutics

$34.50 /

-0.18 (-0.52%)

Researchers are looking…

Researchers are looking at their current scientific "toolkit" to see if any potential therapies for other diseases could also help treat patients with COVID-19, and one example of this is a treatment developed by Fate Therapeutics called FT516, which received support in its early stages from a Late Stage Preclinical grant awarded by CIRM, Yimy Villa writes in The Stem Cellar, the official blog of CIRM, or California's Stem Cell Agency. FT516 uses induced pluripotent stem cells, which are a kind of stem cell made from reprogrammed skin or blood cells that have the potential to become any kind of cell in the body. For FT516, iPSCs are transformed into natural killer cells, which are a type of white blood cell that are a vital part of the immune system and play a role in fighting off viral infections, the blog post reads. Prior to the coronavirus pandemic, FT516 was used in a clinical trial to treat patients with acute myeloid leukemia and B-cell lymphoma, which are two different kinds of blood cancer, the author notes, adding that due to the natural ability of NK cells to fight off viruses, it is believed that FT516 may also help play a role in diminishing viral replication of the novel coronavirus in COVID-19 patients.Reference Link

ShowHide Related Items >><<
FATE Fate Therapeutics
$34.50 /

-0.18 (-0.52%)

FATE Fate Therapeutics
$34.50 /

-0.18 (-0.52%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
FATE Fate Therapeutics
$34.50 /

-0.18 (-0.52%)

  • 09
    Jun
  • 12
    Sep
FATE Fate Therapeutics
$34.50 /

-0.18 (-0.52%)

Tuesday
Recommendations
Catalyst Pharmaceuticals price target lowered to $6 from $7 at Piper Sandler » 10:49
08/11/20
08/11
10:49
08/11/20
10:49
CPRX

Catalyst Pharmaceuticals

$3.57 /

-0.69 (-16.20%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Catalyst Pharmaceuticals to $6 from $7 as he has tempered his near- and long-term growth trajectory to account for the last five quarters of Firdapse revenues, including the $29.6M reported for Q2. The company also announced that the Phase 3 trial evaluating Firdapse in MuSK-MG missed the primary endpoint, but Catanzaro noted that this opportunity was excluded from his model and has no impact on his assumptions. Catanzaro keeps an Overweight rating on Catalyst shares.

ShowHide Related Items >><<
CPRX Catalyst Pharmaceuticals
$3.57 /

-0.69 (-16.20%)

CPRX Catalyst Pharmaceuticals
$3.57 /

-0.69 (-16.20%)

11/13/19 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $7 from $8 at Piper Jaffray
10/09/19 Piper Sandler
Catalyst should see limited impact from Ruzurgi launch, says Piper Jaffray
CPRX Catalyst Pharmaceuticals
$3.57 /

-0.69 (-16.20%)

  • 13
    Sep
CPRX Catalyst Pharmaceuticals
$3.57 /

-0.69 (-16.20%)

Recommendations
Groupon price target raised to $27 from $22 at Wedbush » 07:24
08/11/20
08/11
07:24
08/11/20
07:24
GRPN

Groupon

$24.85 /

-0.92 (-3.57%)

Wedbush analyst Ygal…

Wedbush analyst Ygal Arounian raised the firm's price target on Groupon to $27 from $22 and keeps a Neutral rating on the shares. The analyst notes that Groupon reported better than expected Q2 results, with revenue benefiting from an acceleration in Goods and EBITDA coming in marginally positive versus his materially negative estimate.

ShowHide Related Items >><<
GRPN Groupon
$24.85 /

-0.92 (-3.57%)

GRPN Groupon
$24.85 /

-0.92 (-3.57%)

06/18/20 Wedbush
Groupon price target lowered to $22 from $35 at Wedbush
06/18/20 Barclays
Groupon business model remains uncertain, says Barclays
06/17/20 DA Davidson
Groupon price target raised to $32 from $23 at DA Davidson
02/25/20 Ascendiant
Groupon price target lowered to $1.75 from $3.25 at Ascendiant
GRPN Groupon
$24.85 /

-0.92 (-3.57%)

GRPN Groupon
$24.85 /

-0.92 (-3.57%)

GRPN Groupon
$24.85 /

-0.92 (-3.57%)

GRPN Groupon
$24.85 /

-0.92 (-3.57%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.